We narrowed to 3,492 results for: cre recombinase

#100061-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) (#100061). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 6, 2018

Academic Institutions and Nonprofits only

#105715-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (#105715). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s plasmid DNA. EF1a-driven, Cre-dependent GCaMP6s fused to the presynaptic protein synaptophysin. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

Oct. 20, 2020

Academic Institutions and Nonprofits only

#50457-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#99121-AAV1

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-DIO-tTA (#99121). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-DIO-tTA plasmid DNA. Cre-dependent expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

April 4, 2019

Academic Institutions and Nonprofits only

#137136-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-oScarlet (#137136). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-oScarlet plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of oScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#105677-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Oct. 21, 2024

Academic Institutions and Nonprofits only

#218877-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#137163-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#100839-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.Flex.GCaMP6m.WPRE.SV40 (#100839). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6m.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 14, 2018

Academic Institutions and Nonprofits only

#160857-AAV8

Ready-to-use AAV8 particles produced from pAAV-FLEx-ER-TurboID (#160857). In addition to the viral particles, you will also receive purified pAAV-FLEx-ER-TurboID plasmid DNA. CMV-driven, Cre-dependent expression of ER-localized TurboID (with HA and V5 tag). These AAV preparations are suitable purity for injection into animals.

Jonathan Long

Wei et al Nat Chem Biol. 2021 Mar;17(3):326-334. d

Aug. 6, 2025

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#137156-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-iC++-EYFP (#137156). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-iC++-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 25, 2020

Academic Institutions and Nonprofits only